Jeff Arnold: Yeah. No. That’s a good question. We have learned a lot through the strategic review, and if I had to quickly summarize it, I would say that enterprise is the core and what makes up the core is the digital front door, the therapeutics, the advocacy and the home care, similar to, let’s say, what Lennar bought. And it’s really valuable and we are building pipeline and we have got great clients and we are showing renewals and we are growing our big accounts and we are excited about that and we see — we are not just looking at the strategic review on what are assets that we could sell and what are those worth. But we are also looking at what could we buy and what would we use the proceeds for if we were to sell something, say, like Provider and so there’s a lot of activity going on right now, business combination centered around the core of enterprise.
And the theme I would say that we are focused on is two; one is how to go — how to create scale that’s the big theme of Sharecare. How do we get the scale and how do we contribute meaningful EBITDA and so we are looking at potential business combinations that could get us there. And then the second is, as there’s also opportunities for acquisition — for logo acquisitions where we think our superior platform could replace other platforms that would drive meaningful EBITDA. And so those are kind of two ends of the spectrum as it relates to enterprise, that we have been spending a lot of time on and are excited about and the folks that we have conversations with, I think, really appreciate the capabilities that we have and the clients that are there.
And then the theme of scale, because I think digital health in general or health tech suffers from scale and subscale and that’s something that Sharecare really wants to try to lead the path on is let’s get digital health to scale and through — likely, through a combination.
Operator: The next question is from Eric Percher of Nephron Research. Please go ahead.
Eric Percher: Thank you. Jeff, I also had a question relative to the review and maybe to focus on your comments on Provider, it sounds like there was a comment around validating the strategic value, also comment on the potential value of a sale. Can you remind us what your considerations are, I know there’s an element of ongoing access that is key here, what are you looking for to be able to go forward with the sale?
Jeff Arnold: Well, one is we want to maximize price. So what’s — how do we maximize price. That’s one consideration. The second consideration is, how do we maintain data rights, and potentially, if we were to sell it, are there partners to sell it to that could increase the amount of data that we could have access to and maybe potentially together create new products, data products. And then the third consideration is use of proceeds. So if I lose that asset and I have that revenue and EBITDA, how do I replace it and so those are the three. And we feel like we are getting good validation that we can get a good price, people value what we have built over the last several years and we believe that there’s partners out there that would get creative with us on data rights and data products.
And then we are looking at things with an enterprise that if we were to buy them, could we use the proceeds of Provider to have less dilution are — for to make that acquisition happen.
Eric Percher: That’s helpful. Maybe a follow-up there, have you seen a significant shift in valuations? It does feel like we have seen quite a few digital health transactions announced over the last two months, does it feel like
Jeff Arnold: Yeah.
Eric Percher: sellers are at market?
